Dr Mario Pellegatti has spent more than 30 years in pharmaceutical industry, at GSK, where he managed the DMPK department and oversaw the project portfolio including multiple projects/programs, some of which successfully reached registration and marketing authorization.
Mario is the author of more than 60 publications, and currently provides his expertise in pharmacokinetics and drug development to small and medium-sized biotechnology companies. He is also the co-founder of a start-up company, developing a drug with a new mechanism of action in diseases in CNS (Central Nervous System).